Wuhan Keqian Biology Co Ltd (688526) — Capital Reinvestment Ratio
Latest as of September 2025:
0.07x
Wuhan Keqian Biology Co Ltd (688526) has a Capital Reinvestment Ratio of 0.07x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥174.36 Million) in capital expenditures (CN¥11.35 Million). See 688526 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥174.36 Million
CNY
Capital Expenditures
CN¥11.35 Million
CNY
Data as of
Sep 2025
Most recent filing
Wuhan Keqian Biology Co Ltd Capital Reinvestment Ratio (2016–2024)
This chart tracks Wuhan Keqian Biology Co Ltd's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Wuhan Keqian Biology Co Ltd (2016–2024)
Year-by-year Capital Reinvestment Ratio for Wuhan Keqian Biology Co Ltd from 2016 to 2024. For live market cap and broader valuation context, see Wuhan Keqian Biology Co Ltd stock valuation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | CN¥392.68 Million | CN¥106.94 Million | ▲ +40.2% |
| 2023 | 0.19x | CN¥538.03 Million | CN¥104.50 Million | ▼ -20.0% |
| 2022 | 0.24x | CN¥423.71 Million | CN¥102.85 Million | ▼ -65.6% |
| 2021 | 0.70x | CN¥531.27 Million | CN¥374.45 Million | ▲ +152.7% |
| 2020 | 0.28x | CN¥400.14 Million | CN¥111.60 Million | ▼ -68.6% |
| 2019 | 0.89x | CN¥154.89 Million | CN¥137.74 Million | ▲ +895.7% |
| 2018 | 0.09x | CN¥351.83 Million | CN¥31.42 Million | ▼ -76.6% |
| 2017 | 0.38x | CN¥337.61 Million | CN¥129.11 Million | ▲ +189.7% |
| 2016 | 0.13x | CN¥220.69 Million | CN¥29.13 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow